New York State Common Retirement Fund Acquires 29,501 Shares of Harmony Biosciences Holdings, Inc. $HRMY

New York State Common Retirement Fund increased its holdings in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) by 43.9% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 96,674 shares of the company’s stock after purchasing an additional 29,501 shares during the period. New York State Common Retirement Fund owned approximately 0.17% of Harmony Biosciences worth $2,664,000 at the end of the most recent quarter.

A number of other institutional investors also recently added to or reduced their stakes in HRMY. Boston Partners bought a new stake in Harmony Biosciences during the second quarter worth about $19,398,000. Arrowstreet Capital Limited Partnership grew its position in Harmony Biosciences by 127.6% during the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 906,909 shares of the company’s stock worth $28,658,000 after acquiring an additional 508,498 shares during the last quarter. Nomura Holdings Inc. increased its holdings in Harmony Biosciences by 382.3% during the 2nd quarter. Nomura Holdings Inc. now owns 422,919 shares of the company’s stock valued at $13,364,000 after purchasing an additional 335,237 shares in the last quarter. Marshall Wace LLP raised its position in Harmony Biosciences by 36.3% in the 2nd quarter. Marshall Wace LLP now owns 1,209,484 shares of the company’s stock valued at $38,220,000 after purchasing an additional 321,947 shares during the last quarter. Finally, LSV Asset Management boosted its stake in Harmony Biosciences by 24.6% in the second quarter. LSV Asset Management now owns 1,488,502 shares of the company’s stock worth $47,037,000 after purchasing an additional 293,541 shares in the last quarter. 86.23% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Harmony Biosciences

In other news, CFO Sandip Kapadia sold 20,961 shares of Harmony Biosciences stock in a transaction dated Thursday, January 15th. The shares were sold at an average price of $35.92, for a total value of $752,919.12. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Jeffrey M. Dayno sold 25,933 shares of the business’s stock in a transaction dated Friday, December 12th. The stock was sold at an average price of $40.11, for a total transaction of $1,040,172.63. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 50,640 shares of company stock valued at $1,932,256 over the last three months. 23.60% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on HRMY. Wall Street Zen raised shares of Harmony Biosciences from a “hold” rating to a “buy” rating in a report on Saturday, December 13th. Mizuho increased their price target on shares of Harmony Biosciences from $39.00 to $46.00 and gave the company an “outperform” rating in a research note on Monday, December 1st. UBS Group dropped their price objective on shares of Harmony Biosciences from $50.00 to $43.00 and set a “buy” rating for the company in a research report on Wednesday, October 15th. Zacks Research raised Harmony Biosciences from a “hold” rating to a “strong-buy” rating in a report on Thursday, January 22nd. Finally, Oppenheimer reissued an “outperform” rating and issued a $62.00 target price on shares of Harmony Biosciences in a research note on Monday, November 24th. Two analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $45.25.

Harmony Biosciences Trading Up 2.4%

Shares of NASDAQ:HRMY opened at $37.27 on Friday. The firm has a market cap of $2.15 billion, a price-to-earnings ratio of 11.72, a PEG ratio of 0.34 and a beta of 0.84. Harmony Biosciences Holdings, Inc. has a 12 month low of $25.52 and a 12 month high of $40.87. The company’s fifty day simple moving average is $37.60 and its 200 day simple moving average is $34.31. The company has a quick ratio of 3.72, a current ratio of 3.75 and a debt-to-equity ratio of 0.18.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc is a commercial‐stage biopharmaceutical company focused on developing and delivering therapies for people with rare neurological and endocrine diseases. Founded in 2017 and headquartered in Plymouth Meeting, Pennsylvania, Harmony Biosciences went public in 2020 and trades on the Nasdaq under the ticker HRMY. The company’s mission centers on identifying and advancing medicines that address critical unmet needs in patient populations underserved by existing treatments.

The company’s flagship product is WAKIX (pitolisant), the first and only histamine H3 receptor antagonist/inverse agonist approved by the U.S.